2013-28394. Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate; Reopening of the Comment Period
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice; reopening of the comment period.
SUMMARY:
The Food and Drug Administration (FDA) is reopening the comment period for the notice of availability entitled “Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate”, published in the Federal Register of September 10, 2013 (78 FR 55263). In that notice, FDA requested public comment on the draft guidance. FDA is reopening the comment period due to the inability of some commenters to submit comments through the www.regulations.gov Web site from November 4, 2013, through November 13, 2013, due to technical difficulties.
DATES:
Submit either electronic or written comments to the docket by December 11, 2013.
ADDRESSES:
Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Bhawana Saluja, Center for Drug Evaluation and Research (HFD-643), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-8465.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of September 10, 2013 (78 FR 55263), FDA announced the notice of availability for the draft guidance entitled “Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate.” Interested persons were given until November 12, 2013, to provide comments. The Agency is reopening the comment period until December 11, 2013 to allow interested persons additional time to submit comments.
II. Request for Comments
Following publication of the September 10, 2013, notice of availability, there were technical difficulties with the www.regulations.gov Web site from November 4, 2013, through November 13, 2013, which would have prevented comments from being submitted.
III. How To Submit Comments
Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.
Start SignatureDated: November 20, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-28394 Filed 11-26-13; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Published:
- 11/27/2013
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice; reopening of the comment period.
- Document Number:
- 2013-28394
- Dates:
- Submit either electronic or written comments to the docket by December 11, 2013.
- Pages:
- 70953-70953 (1 pages)
- Docket Numbers:
- Docket No. FDA-2007-D-0369
- PDF File:
- 2013-28394.pdf
- Supporting Documents:
- » Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
- » Product-Specific Guidance for Linaclotide; Draft Guidance for Industry
- » Product-Specific Guidance for Doxycycline Hyclate; Revised Draft Guidance for Industry; Availability
- » Product-Specific Guidances for Salmeterol Xinafoate and Fluticasone Propionate; Draft Guidances for Industry; Availability
- » Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
- » Bioequivalence Recommendations for Difluprednate; Revised Draft Guidance for Industry; Availability
- » Bioequivalence Recommendations for Cyclobenzaprine Hydrochloride; Revised Draft Guidance for Industry; Availability
- » Bioequivalence Recommendations for Paliperidone Palmitate; Draft Guidance for Industry; Availability
- » Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability
- » Bioequivalence Recommendations for Progesterone; Draft Guidance for Industry; Availability